Company profile
MeiraGTx
Engineering Hope
- Industry
- Biotechnology
- Employees
- 420
- Headquarters
- London/New York
- Founded
- 2015
- Office locations
- 2
MeiraGTx company summary
MeiraGTx is a company in the Biotechnology industry, headquartered in London/New York, founded in 2015. On LinkedIn the company has around 420 employees. The company lists 2 office locations. Its listed specialties include biotech, gene therapy, life sciences, rare disease, neurodegenerative disease.
What technology does MeiraGTx use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.
Specialties
Where is MeiraGTx located?
MeiraGTx lists 2 office locations.
Compare companies similar to MeiraGTx
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
MeiraGTx meiragtx.com | Biotechnology | 420 | 2015 | London/New York |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about MeiraGTx
What does MeiraGTx do?
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.
How many employees does MeiraGTx have?
MeiraGTx has around 420 employees on LinkedIn.
Where is MeiraGTx headquartered?
MeiraGTx is headquartered in London/New York.
Where does MeiraGTx have offices?
MeiraGTx lists 2 office locations, including London/New York, N17NQ, GB; NEW YORK, New York, US.
When was MeiraGTx founded?
MeiraGTx was founded in 2015.
Build a lead list from companies like MeiraGTx
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.